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Cerebrospinal ﬂuid and plasmatic levels of oxytocin (OT) have been found to change in
mood disorders. In post-mortem studies, the numbers of OT-expressing neurons in the
paraventricular nucleus have been reported to be increased. Moreover, OT is considered as
an endogenous antistress hormone. It has also revealed antidepressive effects. OT may
contribute to the dysregulation of the HPA system in major depression. The aim of the
study was to assess a possible relationship between anxiety and plasma oxytocin (OT)
levels in depressive patients. Severity of depression was estimated with the Hamilton
Depression Rating Scale and anxiety by using the Spielberger State-Anxiety Inventory.
Results showed a signiﬁcant negative correlation between oxytocin and the scored
symptoms depression (r ¼ 0.58, p ¼ 0.003) and anxiety (r ¼ 0.61, p ¼ 0.005).
& 2007 Elsevier Ltd. All rights reserved.1. Introduction
Oxytocin (OT) is a nonapeptide synthetised in the magnocel-
lular and the parvocellular neurons of the paraventricular and
supraoptic nuclei of the hypothalamus and released directly
into bloodstream from axon terminals in the posteriorElsevier Ltd. All rights reserved.
66 79 60; fax: +32 3 366 72 83.
urlo@ulg.ac.bepituitary. Hormones classically conﬁned to the magnocellu-
lar–neurohypophysial system are found in the parvocellular-
long portal system and are known to be implicated in the
hypophysiotropic control of ACTH release. Apart from its
presence in the hypothalamus, OT is found in several other
brain regions (e.g., bed nucleus of the striae terminalis,
central and medial nuclei of the amygdala, septum,
hippocampus), suggesting that it has a role in neurotransmis-
sion, psychogenic stress and anxiety (Amico et al., 2004).
In animals, the neuropeptide oxytocin has been shown to
exert behavioral and physiologic stress-attenuating and
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positive social interaction (Heinrichs et al., 2003). Research
in humans remains relatively limited; however, initial
studies suggest similar stress-reducing effects of the
neuropeptide in humans (Uvnas-Moberg, 1997; Legros,
2002; Heinrichs et al., 2003), so that it is considered
as an endogenous antistress neuropeptide in humans
(Legros, 2001) and emerges in the pattern of the stress
response.
Some studies have also revealed its antidepressive (Arletti
and Bertolini, 1987) and antistress effects. There is
speculation that some symptoms commonly reported in
depression (social withdrawal, reduced appetite, cognitive
impairment) may reﬂect central OT function (Bell et al.,
2006). There are relatively few data on plasma OT levels in
depression. Zetzsche et al. (1996) have shown a signiﬁcant
reduction of plasma OT in 12 depressed patients compared
with age-matched controls. In addition, a blunting of OT
secretion may be functionally related to the loss of appetite
and the reduction of libido in depressive illness. In contrast,
no signiﬁcant difference was found between mean plasma
levels of OT in depressed patients (N ¼ 52) and controls
(N ¼ 37) by van Londen et al. (1997), but Andeberg and
Uvnas-Moberg (2000) reported a negative correlation
between the levels of OT and the symptom scores of anxiety
and depression in female ﬁbromyalgia syndrome patients. In
addition, a positive correlation has been found between the
levels of OT and happiness. Concerning CSF concentrations
of OT, no signiﬁcant difference was found between
depressed patients and normal controls (Purba et al.,
1996). In postmortem studies, the numbers of AVP- and
OT-expressing neurons in the paraventricular nucleus of the
hypothalamus have been reported to be increased (Purba
et al., 1996).
Previous researchers have found evidence that indicates a
relationship between OT and mood disorders, but more
direct examination is needed. The present study will
investigate further the possible relationship using the data
from a sample of 25 patients that we have reported on in the
previous paper (Scantamburlo et al., 2005). The study
supported partially the hypothesis of a reduced vasopressi-
nergic activity in depression. Moreover, we did not ﬁnd any
inﬂuence of acute apomorphine or clonidine injections on
AVP- or OT-neurophysins in the depressed patients compared
with controls.2. Method
2.1. Subjects
The study was performed in 25 major depressive patients,
representing consecutive admissions to the Biological
Psychiatry and Psychopharmacology Unit of the University
of Lie`ge, Belgium. The diagnosis of major depressive
disorder was based on the DSM-IV criteria and the self-
questionnaire from the Mini International Neuropsychiatric
Interview. Moreover, patients had a score of at least 17 on
the 17-item Hamilton Depression Rating Scale (HDRS)
(Hamilton, 1960). The sample included 18 women with a
mean age of 41.4 years (S.D. ¼ 11.3) and 4 men with a
mean age of 38.6 years (S.D. ¼ 10.4), with ages rangingfrom 19 to 59 years. Among the 18 women, 12 were
premenopausal and 6 were postmenopausal. All premeno-
pausal women were investigated during the ﬁrst phase of
the menstrual cycle as assessed by the patient-reported
date of last menstruation. Patients with irregular menses
were excluded.
All patients were free of medical illness as evidence by
history, medical examination, ECG, chest X-ray, EEG, and
routine laboratory tests. They had also been free of drugs,
including benzodiazepines, for at least 2 weeks at the
time of the study. Patients with a basal blood pressure
o100/70mmHg were excluded from the study.
The protocol was approved by the Ethical Committee of
the University of Lie`ge, Belgium. All patients were fully
informed of the purpose of the study and gave written
consent.2.2. Neuroendocrine procedure
The patients arrived at the Biological Psychiatry and
Psychopharmacology Unit half an hour before the blood
sample were drawn, which was done at 0800 h in the
morning. Blood samples were centrifuged within 2 h and the
serum was immediately frozen and kept at 18 1C until
analysis. OT was measured as previously described with a
double antibody radioimmunoassay. Intraassay variability
was 3.41% and interassay variability was 2.84%. The
sensitivity of OT enzyme-immunoassay is 1 pmol/l.2.3. Anxiety assessment
Self-report anxiety was determined by the State-Trait
Anxiety Inventory (STAI) (Spielberger et al., 1983). The STAI
offers a reliable and widely used measure of anxiety. It is a
well-standardized, 40 item, self-report instrument designed
to measure both state and trait anxiety. For the State
Anxiety Inventory (STAI-A), subjects are asked how they feel
at the time being questioned.2.4. Statistical analyses
The relationship between OT values and the psychological
data were assessed by Pearson product–moment correlation
coefﬁcients (two-tailed) and performed using Statistica for
Windows (Statsoft Inc 1993, Stasoft, Tulsa, USA).3. Results
The mean OT plasma concentrations were 3.6771.34 ng/ml.
The mean score of HDRS was 30.9 (S.D. ¼ 4.8). The
correlation between OT and HDRS among 25 patients
appears in Fig. 1. Results showed a signiﬁcant negative
correlation between the symptom depression and plasma OT
levels (r ¼ 0.58, p ¼ 0.003).
The mean score of STAI-A was 57.68 (S.D. ¼ 12.17). The
correlation between OT and STAI-A among 25 patients
appears in Fig. 2. Results showed a signiﬁcant negative
correlation between anxiety and OT levels (r ¼ 0.61,
p ¼ 0.005).
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Fig. 2 Correlation between OT and STAI-A among 25 patients
(r ¼ 0.61, p ¼ 0.005).
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Fig. 1 Correlation between OT and HDRS among 25 patients
(r ¼ 0.58, p ¼ 0.003).
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The mean ﬁnding of the present study is a negative
association between plasma OT levels in depressed patients
and the scores of depression and anxiety. This is in
accordance with our previous work and abnormalities of
neurohypophysial secretions in major depressive disorder.
In animals, most studies suggest that OT attenuates
glucocorticoid secretion (Windle et al., 1997) and diminishes
anxiety (Neumann, 2002). In humans, OT has been proposed
to play a role in the reduction of anxiety in anxious mothers
during breast feeding (Altemus, 1995). Moreover, OT seems
to enhance the buffering effect of social support on stress
responsiveness (Heinrichs et al., 2003).
OT is involved in mood disorders and may also act as a
potent secretagogue of ACTH release at the anterior lobe of
the pituitary (Andeberg and Uvnas-Moberg, 2000). Intracer-
ebral OT inhibits the stress-induced activity of the hypotha-
lamic-pituitary adrenal (HPA) axis responsiveness suggesting
an inhibitory inﬂuence of OT on stress-responsive neurohor-
monal system (Heinrichs et al., 2003). As OT is known toattenuate the stress response in humans, they postulated
that the OT reduction in the depressed patients may
contribute to the dysregulation of HPA system consistently
found in major depression (Zetzsche et al., 1996).
While vasopressin is known as an ACTH stimulating factor
synergistic to CRF, it is likely that endogenous oxytoninergic
system, which can be activated by physiological and/or
pharmacological manipulation, can ‘‘buffer’’ the stress
activated vasopressin-ACTH-cortisol action (Legros, 2001;
Heinrichs et al., 2003). A variety of neurotransmitters and
neuropeptides inﬂuence the HPA axis. Central OT pathways
are believed to facilitate anxiolysis and to attenuate the
response of the HPA axis to psychogenic stressors. The medial
amygdalia may be an important region for OT actions that
govern a variety of social and stress behaviours (Amico et al.,
2004). In major depression there is an upregulation in the HPA
axis, which in turn down-regulates the 5-HT1A receptors and
the activity of serotonin. The increased number of oxytocin
neurons may be a compensatory physiological mechanism to
balance and increase the serotoninergic activity in order to
accomplish better mood and well-being.
Some limitations of the study need to be discussed. This is
a clinical population of mostly women with limited general-
izability to other populations. Other information, such as
childbirth and lactation history, which may inﬂuence the
oxytoninergic system, was not gathered or analyzed. The
most important admission is that the study is correlational
and that no direction of causality can be made.
Pharmacological or nonpharmacological activation of
endogenous OT release might be considered as a way of
alleviating stress (Legros, 2001, 2002). The OTand serotonin
(5-hydroxytryptophan (5-HT)) systems are interconnected.
Oxytocin ﬁbers project to the raphe nuclei and OT may
inﬂuence the secretion of 5-HT. Recent studies have
demonstrated that OT is released in response to treatment
with selective serotonin reuptake inhibitors (SSRI), opening
up the possibility that OT also mediate further effects
caused by serotonin (Uvnas-Moberg et al., 1999).
In conclusion, the present study supports the importance of
OT in mechanism underlying anxiolysis. Future work focusing
on male/female differences or looking at childbirth and
lactation history could be done. A further study should explore
OT administration. Neurendocrine research is also needed to
elucidate the mode of action of OT, its antistress properties,
and the interactions with the HPA axis and the monaminergic
system. Finally, we should emphasize the effect size of the
ﬁnding (Lawrence Erlbaum Associates, 1984). The magnitude
of the r’s suggests a strong association between OTand mood.
These appear to be a robust ﬁnding that merit further
research and may yield important clinical applications.
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